Diversify Advisory Services LLC Acquires Shares of 15,146 Boston Scientific Corporation $BSX

Diversify Advisory Services LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,146 shares of the medical equipment provider’s stock, valued at approximately $689,000.

Several other hedge funds have also recently modified their holdings of BSX. Outfitters Financial LLC boosted its holdings in Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after buying an additional 110 shares during the last quarter. CYBER HORNET ETFs LLC lifted its position in shares of Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $391,000 after acquiring an additional 132 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Boston Scientific by 4.7% in the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 139 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of Boston Scientific by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock worth $4,516,000 after acquiring an additional 140 shares during the last quarter. Finally, Kingsview Wealth Management LLC increased its position in shares of Boston Scientific by 2.4% during the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 194,522 shares of company stock valued at $9,385,210 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a report on Wednesday, July 29th. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Wells Fargo & Company lowered their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 30th. Finally, Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Stock Down 4.9%

Shares of NYSE:BSX opened at $49.47 on Friday. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a market cap of $71.69 billion, a P/E ratio of 20.03, a PEG ratio of 1.13 and a beta of 0.56. The business has a fifty day moving average of $46.26 and a two-hundred day moving average of $57.91. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.